← Back to Search

Other

Gefapixant for Chronic Bronchitis

Phase 3
Waitlist Available
Research Sponsored by Merck Sharp & Dohme Corp.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to ~16 weeks
Awards & highlights

Study Summary

This trial will test whether gefapixant can help reduce episodes of stress urinary incontinence caused by chronic cough in adult women.

Eligible Conditions
  • Chronic Bronchitis
  • Chronic Cough

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to ~16 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to ~16 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percent Change From Baseline in Average Daily Cough-induced Stress Urinary Incontinence (SUI) Episodes at Week 12
Secondary outcome measures
Percentage of Participants Who Discontinued Study Intervention Due to AEs
Percentage of Participants With Adverse Events

Side effects data

From 2022 Phase 3 trial • 376 Patients • NCT04193176
31%
Dysgeusia
19%
Ageusia
8%
Hypogeusia
7%
Headache
5%
Nausea
1%
Ankle fracture
1%
Cholecystitis chronic
1%
Rectal fissure
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Gefapixant

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: GefapixantExperimental Treatment1 Intervention
Participants will receive gefapixant at a dose of 45 mg administered as an oral tablet twice daily for 12 weeks.
Group II: PlaceboPlacebo Group1 Intervention
Participants will receive placebo matching gefapixant, administered as an oral tablet twice daily for 12 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Gefapixant
2017
Completed Phase 3
~2640

Find a Location

Who is running the clinical trial?

Merck Sharp & Dohme Corp.Lead Sponsor
2,286 Previous Clinical Trials
4,581,452 Total Patients Enrolled
Merck Sharp & Dohme LLCLead Sponsor
3,886 Previous Clinical Trials
5,054,177 Total Patients Enrolled
1 Trials studying Chronic Bronchitis
106 Patients Enrolled for Chronic Bronchitis
Medical DirectorStudy DirectorMerck Sharp & Dohme LLC
2,777 Previous Clinical Trials
8,063,110 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
North Carolina
Maine
Missouri
How old are they?
18 - 65
What site did they apply to?
PMG Research of Wilmington ( Site 0004)
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
Recent research and studies
clinicaltrials.govStudy
Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042)
2020. "Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04193176.
~76 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top